Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Impedimed Limited ( (AU:IPD) ) has provided an announcement.
ImpediMed Limited has disclosed a change in the interests of director Janelle Delaney, who increased her direct holding in the company by 100,563 ordinary shares on 14 January 2026. The additional shares were issued at $0.0355 per share in lieu of 15% of her director fees for the quarter ended 31 December 2025, leaving her with 1,982,044 shares held directly and 2,921,387 shares held indirectly through the Delaney Family Superannuation Fund, signaling continued alignment of director compensation with shareholder equity.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian-listed medical technology company that develops and commercialises bioimpedance spectroscopy devices, primarily used for the non-invasive assessment and monitoring of body fluid status, with applications including the detection and management of conditions such as lymphedema and fluid overload. The company targets healthcare providers and hospitals seeking objective, device-based diagnostic and monitoring tools.
Average Trading Volume: 1,179,706
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$71.34M
Learn more about IPD stock on TipRanks’ Stock Analysis page.